Drug intelligence / Profile preview

HS-10345

Development stage: Phase 1
Lead developer: Hansoh Pharmaceutical Group
Modality: Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration: Intranasal

Overview

HS-10345 is the code name for an intranasal formulation of (R)-ketamine, developed by Jiangsu Hansoh Pharmaceutical for the treatment of treatment-resistant depression. (R)-ketamine is an enantiomer of ketamine, a well-known N-methyl-D-aspartate (NMDA) receptor antagonist with rapid-acting antidepressant effects. The drug is being evaluated for its safety, tolerability, and pharmacokinetics in patients with treatment-resistant depression[1][2][3][7].

Other names: (R)-ketamine nasal spray

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on HS-10345.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-10345.

Explore the full profile